D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Microbiology D-index 97 Citations 32,916 444 World Ranking 100 National Ranking 51
Medicine D-index 102 Citations 41,697 561 World Ranking 3396 National Ranking 1940

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Antibiotics
  • Surgery

Vancomycin, Antibacterial agent, Staphylococcus aureus, Microbiology and Daptomycin are his primary areas of study. His research in Vancomycin intersects with topics in Infective endocarditis, Surgery, Internal medicine and Minimum inhibitory concentration. His Antibacterial agent study is concerned with the field of Antibiotics as a whole.

His Staphylococcus aureus research is multidisciplinary, incorporating elements of Glycopeptide and Pharmacology. His Microbiology research is multidisciplinary, relying on both Pseudomonas aeruginosa and SCCmec. His work carried out in the field of Daptomycin brings together such families of science as Nafcillin, Enterococcus faecium, Vancomycin-resistant Staphylococcus aureus, Gram-positive bacteria and Gentamicin.

His most cited work include:

  • Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children (2524 citations)
  • Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. (1246 citations)
  • Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications A Scientific Statement for Healthcare Professionals From the American Heart Association (1175 citations)

What are the main themes of his work throughout his whole career to date?

Michael J. Rybak focuses on Microbiology, Vancomycin, Staphylococcus aureus, Daptomycin and Antibiotics. Michael J. Rybak works mostly in the field of Microbiology, limiting it down to topics relating to Pharmacology and, in certain cases, Levofloxacin, as a part of the same area of interest. Michael J. Rybak has researched Vancomycin in several fields, including Glycopeptide, Internal medicine, Staphylococcal infections and Methicillin-resistant Staphylococcus aureus.

His Internal medicine research incorporates themes from Bacteremia and Surgery. His work is dedicated to discovering how Staphylococcus aureus, Endocarditis are connected with Infective endocarditis and other disciplines. In his work, Enterococcus faecalis is strongly intertwined with Enterococcus faecium, which is a subfield of Daptomycin.

He most often published in these fields:

  • Microbiology (105.60%)
  • Vancomycin (90.80%)
  • Staphylococcus aureus (71.70%)

What were the highlights of his more recent work (between 2018-2021)?

  • Internal medicine (53.74%)
  • Vancomycin (90.80%)
  • Microbiology (105.60%)

In recent papers he was focusing on the following fields of study:

His primary areas of study are Internal medicine, Vancomycin, Microbiology, Methicillin-resistant Staphylococcus aureus and Daptomycin. His Internal medicine study which covers Bacteremia that intersects with Ceftazidime/avibactam, Carbapenem-resistant enterobacteriaceae, Medical microbiology and Ceftaroline fosamil. Vancomycin is a primary field of his research addressed under Staphylococcus aureus.

His work deals with themes such as Pseudomonas aeruginosa, Acinetobacter baumannii and Endocarditis, which intersect with Microbiology. His Methicillin-resistant Staphylococcus aureus research focuses on Cefepime and how it connects with Concomitant. His Daptomycin study combines topics from a wide range of disciplines, such as Enterococcus faecium, Dalbavancin, Pharmacodynamics, Combination therapy and Ceftriaxone.

Between 2018 and 2021, his most popular works were:

  • Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa. (25 citations)
  • Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa. (25 citations)
  • Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint (23 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Antibiotics
  • Surgery

Michael J. Rybak spends much of his time researching Internal medicine, Bacteremia, Antibiotics, Methicillin-resistant Staphylococcus aureus and Microbiology. His Internal medicine research is multidisciplinary, relying on both Carbapenem-resistant enterobacteriaceae and Multiple drug resistance. His studies deal with areas such as Daptomycin and Retrospective cohort study as well as Bacteremia.

His work in Methicillin-resistant Staphylococcus aureus tackles topics such as Vancomycin which are related to areas like Concomitant, Cefepime and Hazard ratio. His Microbiology research is multidisciplinary, incorporating perspectives in Pseudomonas aeruginosa, Bacteriophage, Klebsiella pneumoniae and Staphylococcus aureus. His studies in Staphylococcus aureus integrate themes in fields like Glycopeptide and PK/PD models.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children

Catherine Liu;Arnold Bayer;Sara E. Cosgrove;Robert S. Daum.
Clinical Infectious Diseases (2011)

4042 Citations

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Michael Rybak;Joseph R. Dalovisio.
American Journal of Health-system Pharmacy (2009)

1997 Citations

Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications A Scientific Statement for Healthcare Professionals From the American Heart Association

Larry M. Baddour;Walter R. Wilson;Arnold S. Bayer;Vance G. Fowler.
Circulation (2015)

1908 Citations

Vancomycin Therapeutic Guidelines: A Summary of Consensus Recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists

Michael J. Rybak;Ben M. Lomaestro;John C. Rotschafer;Robert C. Moellering.
Clinical Infectious Diseases (2009)

919 Citations

Outcomes Analysis of Delayed Antibiotic Treatment for Hospital-Acquired Staphylococcus aureus Bacteremia

Thomas P. Lodise;Peggy S. McKinnon;Linda Swiderski;Michael J. Rybak.
Clinical Infectious Diseases (2003)

696 Citations

The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin

Michael J. Rybak.
Clinical Infectious Diseases (2006)

673 Citations

Impact of Vancomycin Exposure on Outcomes in Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia: Support for Consensus Guidelines Suggested Targets

Ravina Kullar;Susan L. Davis;Susan L. Davis;Donald P. Levine;Michael J. Rybak;Michael J. Rybak.
Clinical Infectious Diseases (2011)

553 Citations

Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Michael J. Rybak;Michael J. Rybak;Ben M. Lomaestro;John C. Rotschafer;Robert C. Moellering.
Pharmacotherapy (2009)

501 Citations

In Vitro Activities of Daptomycin, Vancomycin, Linezolid, and Quinupristin-Dalfopristin against Staphylococci and Enterococci, Including Vancomycin- Intermediate and -Resistant Strains

Michael J. Rybak;Ellie Hershberger;Tabitha Moldovan;Richard G. Grucz.
Antimicrobial Agents and Chemotherapy (2000)

472 Citations

Prospective Evaluation of the Effect of an Aminoglycoside Dosing Regimen on Rates of Observed Nephrotoxicity and Ototoxicity

Michael J. Rybak;Michael J. Rybak;Betty J. Abate;S. Lena Kang;Michael J. Ruffing.
Antimicrobial Agents and Chemotherapy (1999)

463 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Michael J. Rybak

Jason A. Roberts

Jason A. Roberts

Royal Brisbane and Women's Hospital

Publications: 140

Jeffrey Lipman

Jeffrey Lipman

Royal Brisbane and Women's Hospital

Publications: 133

David P. Nicolau

David P. Nicolau

Hartford Hospital

Publications: 127

George Sakoulas

George Sakoulas

University of California, San Diego

Publications: 96

Arnold S. Bayer

Arnold S. Bayer

University of California, Los Angeles

Publications: 90

Paul B. Savage

Paul B. Savage

Brigham Young University

Publications: 84

Vance G. Fowler

Vance G. Fowler

Duke University

Publications: 68

Matteo Bassetti

Matteo Bassetti

University of Genoa

Publications: 67

Cesar A. Arias

Cesar A. Arias

The University of Texas Health Science Center at Houston

Publications: 63

Ronald N. Jones

Ronald N. Jones

JMI Laboratories

Publications: 60

Matthew E. Falagas

Matthew E. Falagas

Alfa Institute of Biomedical Sciences

Publications: 46

George G. Zhanel

George G. Zhanel

University of Manitoba

Publications: 45

Marin H. Kollef

Marin H. Kollef

Washington University in St. Louis

Publications: 45

David L. Paterson

David L. Paterson

University of Queensland

Publications: 44

José M. Miró

José M. Miró

University of Barcelona

Publications: 43

Yan Q. Xiong

Yan Q. Xiong

University of California, Los Angeles

Publications: 42

Trending Scientists

R. Srikant

R. Srikant

University of Illinois at Urbana-Champaign

Huaqiang Wu

Huaqiang Wu

Tsinghua University

Encarnacion Raymundo-Pinero

Encarnacion Raymundo-Pinero

Centre national de la recherche scientifique, CNRS

John M. Archibald

John M. Archibald

Dalhousie University

M. Aaron MacNeil

M. Aaron MacNeil

Dalhousie University

Piran C. L. White

Piran C. L. White

University of York

Freimut Schliess

Freimut Schliess

Heinrich Heine University Düsseldorf

Shota Nakamura

Shota Nakamura

Osaka University

Juan Luis Guerrero-Rascado

Juan Luis Guerrero-Rascado

University of Granada

Robert I. Griffiths

Robert I. Griffiths

University of Oxford

J. Webb

J. Webb

Ricardo AEA (United Kingdom)

Charles Antaki

Charles Antaki

Loughborough University

William Maixner

William Maixner

Duke University

John R. Crouse

John R. Crouse

Wake Forest University

Michail N. Giannakos

Michail N. Giannakos

Norwegian University of Science and Technology

Something went wrong. Please try again later.